A provider who understands these differences may be willing to prescribe based on your actual metabolic risk rather than a standard BMI cutoff that was not designed for your population
Lifestyle changes can help improve your period symptoms and set you up for success during perimenopause, says Dr
Older adults need to monitor not just appearance, but how they feel
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes